They also discovered that cigarette use declined among a subgroup of smokers in the study, lending weight to the hypothesis ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Long-Term Pick. In this article, we will summarize ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

CagriSema – a combination of Novo Nordisk's GLP-1 agonist semaglutide with dual amylin and calcitonin receptor agonist cagrilintide – achieved a 20.4% reduction in weight in the REDEFINE 1 ...

Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...

Medscape Medical News, February 06, 2025 Some Patients — And Doctors — Turn to Microdosing GLP-1s Some do it to save ... 2.2 million diabetes cases and 1.2 million heart disease cases annually.

The company’s stock declined approximately 20% following clinical trial results for its obesity drug, CagriSema ... by the strong performance of its GLP-1 drugs, Mounjaro and Zepbound.